Confo Therapeutics

Description

Confo Therapeutics develops GPCR-directed small-molecule and antibody therapies with proprietary technology that targets class A and B receptors to find agonists, antagonists, inverse agonists, and allosteric modulators for metabolic and endocrine diseases.

Confo Therapeutics is located in the Belgium ecosystem.

Related

• BIMINI BiotechBIMINI Biotech develops first-in-class small-molecule therapeutics targeting the Wiskott–Aldrich Syndrome protein for oncology and…
• ATXA TherapeuticsATXA Therapeutics develops selective small-molecule thromboxane receptor (TP) antagonists, including lead candidate NTP42, to treat…
• Breye TherapeuticsBreye Therapeutics develops orally administered ophthalmology drugs, including danegaptide and P2X7 receptor antagonists, to treat retinal…
• Agomab TherapeuticsAgomab Therapeutics develops disease-modifying therapies for fibro-inflammatory conditions through TGFβ/ALK5 (TGFβR1) pathway targeting,…
• ALLOXALLOX uses high-throughput experiments with genetics and AI to learn biophysical parameters of protein function, supporting systematic…
• NTrans TechnologiesNTrans Technologies develops a non-viral delivery platform for cell and gene therapies, providing modular delivery solutions for…
• Molecular PartnersMolecular Partners develops DARPin therapeutics, including Radio-DARPins and logic-gated Switch-DARPins, to target DLL3, FAP x CD40, and…
• Hansa BiopharmaHansa Biopharma develops immunomodulating antibody-cleaving enzyme therapies that target and inactivate IgG antibodies, inhibiting…
• BioInvent InternationalBioInvent International discovers and develops antibody therapeutics for cancer treatment, using immunology, cancer biology, antibody…